Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 16/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9036818 | 0.87 | MAPT (0.70) | MAPTLCKFYNAKR1B1GRB2 | |
| SCHEMBL31083416 | 0.83 | MAPT (0.56) | MAPTAKR1B1SMN1; SMN2 | |
| SCHEMBL8116328 | 0.83 | MAPT (0.56) | MAPTAKR1B1SMN1; SMN2ACHE | |
| SCHEMBL3524883 | 0.83 | MAPT (0.56) | MAPTAKR1B1SMN1; SMN2ACHE | |
| SCHEMBL14564409 | 0.83 | MAPT (0.78) | MAPTSMN1; SMN2 | |
| SCHEMBL23117302 | 0.80 | KDM4E (0.47) | MAPTAKR1B1ESR1ESR2HSP90AA1 | |
| SCHEMBL23640288 | 0.80 | MAPT (0.50) | MAPTLCKFYNAKR1B1GRB2 | |
| SCHEMBL15158081 | 0.79 | MAPT (0.56) | MAPTLCKSMN1; SMN2ACHE | |
| SCHEMBL17233427 | 0.78 | ESR1 (0.54) | ESR1ESR2HSP90AA1 | |
| SCHEMBL75124 | 0.78 | MAPT (0.62) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023001028-A1 | HETEROARYL-3-PIPERIDINEDIONE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | MAPT 2404/4885LCK 1008/4885FYN 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.